AstraZeneca and Algen Biotechnologies Partner for AI-Driven Gene-Editing Therapies

Oct 6, 2025
AstraZeneca has entered a $555 million partnership with Algen Biotechnologies to develop gene-editing therapies using AI and CRISPR technology.

AstraZeneca has signed a $555 million agreement with Algen Biotechnologies to advance AI-powered drug discovery in immunology, announced in a press release. This collaboration grants AstraZeneca exclusive rights to develop and commercialize therapies using Algen's CRISPR gene-editing technology.

Algen will leverage its AlgenBrain™ platform to identify novel therapeutic targets, focusing on immune system diseases. The platform integrates AI with high-throughput functional genomics to map disease progression and identify potential therapeutic targets. Algen is set to receive up to $555 million, contingent on achieving specific development, regulatory, and commercial milestones.

This partnership reflects a growing trend in the pharmaceutical industry to incorporate AI in drug development, aiming to enhance the discovery of new targets and improve the efficiency of drug development processes.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.